RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Establishment and Multidimensional Characterization of a Novel Epstein-Barr Virus (EBV)-Negative Human Type I Natural Killer T-Cell Line NKT617.
Establishment and Multidimensional Characterization of a Novel Epstein-Barr Virus (EBV)-Negative Human Type I Natural Killer T-Cell Line NKT617.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤T细胞(NKT)是T淋巴细胞的一个独特亚群,其发育和功能调控尚未被完全了解。经过充分表征的永生化细胞系是体外研究NKT细胞生物学的关键工具。
我们建立并维持了一株新的NKT细胞系NKT617,来源于一名侵袭性大颗粒淋巴细胞白血病患者的外周血。使用扫描电子显微镜和透射电子显微镜评估细胞形态。流式细胞术表征细胞表型,而T细胞受体(TCR)克隆性基因重排确定谱系。RNA测序比较NKT617与其他血液肿瘤细胞系(如自然杀伤(NK)细胞、T细胞、B细胞和单核细胞)的基因表达谱。通过体外集落形成实验和体内斑马鱼异种移植模型评估致瘤潜力。NKT617已连续培养>2年,超过100代,表现出单克隆永生化。它以低剂量重组人白细胞介素-2依赖的方式增殖,并以单细胞和聚集体形式在悬浮培养中生长。流式细胞术分析显示,NKT617表现出NK细胞表型CD56 +、CD158a +、NKp46 +、膜结合CD3 -,以及T细胞特征胞质CD3 +、CD2 +、CD4 +、CD8 +、CD45RA + 和CD45RO +,并具有克隆性TCRβ重排。NKT617对B细胞和髓系标志物阴性,对TCRα链(Vα24-Jα18)阳性,确认其为I型NKT细胞。转录组分析显示与NK细胞和T细胞系共享标志物,但基因表达谱更接近NK细胞。体外和体内实验证实了其致瘤能力。
我们报道了首个人类EB病毒阴性I型NKT细胞系NKT617,该细胞系在研究NKT细胞发育和推进嵌合抗原受体疗法方面具有巨大潜力。该细胞系是探索NKT细胞生物学和开发靶向免疫疗法的宝贵工具。
Natural killer T cells (NKT), a unique subset of T lymphocytes, remain incompletely understood in terms of their development and functional regulation. Well-characterized immortalized cell lines are critical tools for investigating NKT cell biology in vitro.
We established and maintained a novel NKT cell line, NKT617, derived from the peripheral blood of a patient with aggressive large granular lymphocyte leukemia. Cell morphology was assessed using scanning electron microscopy and transmission electron microscopy. Flow cytometry characterized the cell phenotype, whereas T-cell receptor (TCR) clonal gene rearrangement determined lineage. RNA sequencing compared gene expression profiles of NKT617 with other hematological tumor cell lines, such as natural killer (NK) cells, T cells, B cells, and monocytes. Tumorigenic potential was evaluated via in vitro colony formation assays and in vivo zebrafish xenograft models. NKT617 has been continuously cultured for >2 years, exceeding 100 passages, demonstrating monoclonal immortalization.
It proliferates in a low-dose recombinant human interleukin-2-dependent manner and grows in suspension culture as single cells and aggregates. Flow cytometric analysis showed that NKT617 exhibits an NK-cell phenotype CD56 + , CD158a + , NKp46 + , membrane-bound CD3 - , and T-cell features cytoplasmic CD3 + , CD2 + , CD4 + , CD8 + , CD45RA + , and CD45RO + , with clonal TCRβ rearrangement.
NKT617 was negative for B-cell and myeloid markers and positive for the TCRα chain (Vα24-Jα18), confirming its identity as a type I NKT cell. Transcriptome analysis showed shared markers with NK-cell and T-cell lines but a gene expression profile closer to NK cells. In vitro and in vivo assays confirmed its tumorigenic capacity.
We report the first Epstein-Barr virus-negative human type I NKT cell line, NKT617, which offers significant potential for studying NKT cell development and advancing chimeric antigen receptor-based therapies. This cell line serves as a valuable tool for exploring NKT cell biology and developing targeted immunotherapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。